Investing

Kyverna Therapeutics Sinks 13%: Here’s Why

A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.

By Danielle Liverance
Published July 10, 2026, 3:59pm ET · 2 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Two scientists in white lab coats are seen in a brightly lit, modern laboratory. One scientist, with blonde hair and glasses, is in the foreground, looking at a computer monitor displaying microscopic images of cells. Another scientist, with blonde hair in a ponytail, is visible in the background, also working at a computer. The lab features multiple computer screens, microscopes, beakers, test tubes, and other scientific equipment, all with a clean, blue-tinted aesthetic.
Scientists work diligently in a modern laboratory, symbolizing the innovative research driving the biotechnology sector, a key area for funds like FBT and IBB. © gorodenkoff / iStock via Getty Images

Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81. The pullback interrupts a strong run for the clinical-stage autoimmune CAR-T developer, which is still up 25% over the past month and 215% over the past year.

Analyst Target Cut Cools a Hot Trade

The catalyst appears to be a fresh analyst note. JPMorgan reiterated its Overweight rating but trimmed its price target on the stock to $29, while Weiss Ratings and Wall Street Zen issued sell calls. The consensus still sits at Moderate Buy with an average target of $30, but the reset in expectations is landing hard on a stock that had tripled off last summer’s lows.

The move is notable because it comes despite reasonable results for a clinical-stage biotech. Kyverna reported a Q1 2026 loss of -$0.66 per share, better than the -$0.73 consensus. The company also initiated a rolling BLA submission for lead asset miv-cel in stiff person syndrome, with completion expected Q4 2026 and potential commercial launch in 2027. CEO Warner Biddle called the FDA alignment on a single-arm trial “a significant milestone” in the company’s May filing.

An infographic presenting Kyverna Therapeutics (KYTX) Market Movers. The layout features a central title and six distinct sections with text, icons, and small charts on a light background. The main header indicates KYTX stock is down 12.13% to $8.90, opened at $9.81, interrupting a strong past month and year. The 'Analyst Target Cut & Profit-Taking' section shows JPMorgan's trimmed price target to $29, Weiss Ratings' sell calls, and a moderate buy consensus of $30. 'Strong Operational Results & Milestones' lists Q1 2026 earnings (loss -$0.6574, beating consensus) and Miv-cel Rolling BLA submission details. 'Cell-Therapy Peers Also Under Pressure' displays Cabaletta Bio (-4%), Allogene Therapeutics (-5%), Beam Therapeutics (-8%), and Cartesian Therapeutics (-1%). 'Recent Positive Catalysts & Metrics' highlights Russell index additions, new CFO, AIGH stake increase, and a 52-week high of $13.67. Finally, 'What to Watch' outlines Q2 2026 earnings on August 11, 2026, and a key technical support level near $8.72.
24/7 Wall St.
Kyverna Therapeutics (KYTX) stock experienced a significant drop on Friday afternoon, influenced by analyst target cuts despite the company’s strong Q1 2026 earnings and ongoing progress toward BLA submission.

Cell-Therapy Peers Also Under Pressure

The broader autoimmune and oncology cell-therapy group is soft on the session alongside Kyverna. Cabaletta Bio (NASDAQ:CABA), which recently raised $150 million with Eli Lilly participating, is off 4%. Allogene Therapeutics (NASDAQ:ALLO), fresh off strong ALPHA3 data earlier this summer, is down 5%. Beam Therapeutics (NASDAQ:BEAM | BEAM Price Prediction) is the weakest of the group, sliding 8% from a recent 52-week high. Cartesian Therapeutics (NASDAQ:RNAC), Kyverna’s most direct competitor in myasthenia gravis, is holding up better, down only 1%.

After a month in which Kyverna joined the Russell 2000 and Russell 3000 indexes, hired a new CFO and Chief Legal Officer, and drew a 33.3% stake increase from AIGH Capital, expectations had run ahead of the setup. A single price-target trim was enough to trigger profit-taking in a low-float, high-beta name. Kyverna’s beta sits at 1.88, and shares still trade well below the 52-week high of $13.67.

What to Watch

The next scheduled catalyst is Q2 2026 earnings on August 11, 2026, with consensus at -$0.67. Before then, investors will look for updates on the rolling BLA submission for miv-cel and longer-term Phase 2 gMG follow-up data guided for H2 2026. I would keep an eye on whether KYTX can hold the $8.72 50-day moving average into the close.

Contact [email protected] for any questions or corrections.

1INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE

Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org).2The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts.

3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees.

4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.

Danielle Liverance

I've spent more than 15 years inside enterprise software, working alongside the finance, sales operations, and HR leaders who run the revenue engines at some of the largest tech companies in the country.

My day job is helping enterprise executives make smarter decisions about retention, compensation, and growth. These are the same operational levers that show up in every earnings report investors actually read. That perspective shapes my writing for 24/7 Wall St.

The headline numbers are easy. The interesting stuff is underneath: how companies make money, what executives are worried about, and what any of it means for the person checking their 401(k) on a Sunday afternoon. I write about personal finance and business as someone who has spent her career inside the rooms where these decisions get made.

All articles →